De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Lifecore Biomedical Beheer

Beheer criteriumcontroles 0/4

De CEO Lifecore Biomedical's is Paul Josephs, benoemd in May2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.25M, bestaande uit 0.1% salaris en 99.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.052% van de aandelen van het bedrijf, ter waarde $ 79.00K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 1.8 jaar.

Belangrijke informatie

Paul Josephs

Algemeen directeur

US$10.2m

Totale compensatie

Percentage CEO-salaris	0.1%
Dienstverband CEO	less than a year
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	1.8yrs

Recente managementupdates

Recent updates

Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty

Jun 24

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Apr 20

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Apr 08

Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet

Mar 21

Here's What's Concerning About Landec's (NASDAQ:LNDC) Returns On Capital

Nov 30

Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products

Nov 05

Landec Still In Play As An Activist Investment

Aug 20

Is Landec (NASDAQ:LNDC) Using Too Much Debt?

May 25

Analyse CEO-vergoeding

Hoe is Paul Josephs's beloning veranderd ten opzichte van Lifecore Biomedical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
May 26 2024	US$10m	US$11k	US$9m

Compensatie versus markt: De totale vergoeding ($USD 10.25M ) Paul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Paul te vergelijken met de prestaties van het bedrijf.

CEO

Paul Josephs (59 yo)

less than a year

Tenure

US$10,247,057

Compensatie

Mr. Paul Josephs is President, CEO & Director of Lifecore Biomedical, Inc. from May 20, 2024. Mr. Josephs is President & CEO of Woodstock Sterile Solutions, Inc. Mr. Josephs serves as Senior Vice President...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Josephs	President	less than a year	US$10.25m	0.052% $ 75.4k
James Hall	Advisor	less than a year	US$2.50m	2.19% $ 3.2m
Ryan Lake	CFO & Secretary	less than a year	geen gegevens	geen gegevens
Kipling Thacker	VP & Chief Scientist	1.5yrs	geen gegevens	geen gegevens
Aaron Perlitsh	Director of Internal Audit & Chief Compliance Officer	no data	geen gegevens	geen gegevens
Darren Hieber	Senior Vice President of Corporate Development & Partnerships	2.8yrs	geen gegevens	geen gegevens
Brikkelle Thompson	Senior Vice President of Human Resources	less than a year	geen gegevens	geen gegevens
Jackie Klecker	Executive VP & GM	2.8yrs	geen gegevens	geen gegevens
Matt Augustson	Senior Vice President of Information Technology	2.8yrs	geen gegevens	geen gegevens
Albert Bolles	President of Curation Foods	2.2yrs	US$1.34m	1.41% $ 2.0m
Parker Javid	Vice President	no data	US$460.69k	geen gegevens

1.5yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LFCR wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Josephs	President	less than a year	US$10.25m	0.052% $ 75.4k
Nelson Obus	Independent Director	6yrs	US$215.00k	0.29% $ 417.3k
Katrina Houde	Independent Chairman of the Board	5.2yrs	US$220.00k	0.19% $ 281.9k
Jeffrey Edwards	Independent Director	4yrs	US$225.00k	0.16% $ 233.7k
Joshua Schechter	Independent Director	4yrs	US$220.00k	0.19% $ 280.7k
Humberto Antunes	Independent Director	less than a year	geen gegevens	0.0097% $ 14.1k
Christopher Kiper	Independent Director	1.8yrs	US$200.00k	0.091% $ 132.1k
Paul Johnson	Independent Director	less than a year	geen gegevens	geen gegevens
Raymond Diradoorian	Independent Director	2.8yrs	US$220.00k	0.13% $ 188.1k
Jason Aryeh	Independent Director	less than a year	geen gegevens	geen gegevens
Matthew Korenberg	Independent Director	less than a year	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LFCR wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.

Lifecore Biomedical Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Lifecore Biomedical, Inc. Appoints Brikkelle Thompson as Senior Vice President of Human Resources

Lifecore Biomedical Announces Chief Financial Officer Transition

High number of new directors

Lifecore Biomedical, Inc. Announces Board Changes

Lifecore Biomedical, Inc., Annual General Meeting, Aug 15, 2024

Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024

Recent updates

Lifecore Biomedical, Inc. Reiterates Financial Guidance for Full Year Fiscal 2025

Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler Is Gmp-Ready and Operational

Lifecore Biomedical, Inc. Appoints Brikkelle Thompson as Senior Vice President of Human Resources

Lifecore Biomedical Announces Chief Financial Officer Transition

Lifecore Biomedical, Inc. Provides Earnings Guidance for Full Year Fiscal 2025

Lifecore Biomedical, Inc. announced delayed annual 10-K filing

Third quarter 2024 earnings released: EPS: US$0.48 (vs US$0.51 loss in 3Q 2023)

High number of new directors

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Lifecore Biomedical, Inc

Price target decreased by 25% to US$6.00

Lifecore Biomedical, Inc. Announces Board Changes

Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty

Lifecore Biomedical Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Requirements for Continued Listing Under Nasdaq Listing Rule 5620(a)

Lifecore Biomedical, Inc., Annual General Meeting, Aug 15, 2024

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024

Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024

Lifecore Biomedical Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?

Lifecore Biomedical, Inc.(NasdaqGS:LFCR) dropped from Russell 2000 Dynamic Index

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 86% to US$2.00

High number of new directors

Lifecore Biomedical Receives A Notification Letter from Nasdaq Due to Delay in Filing Its Quarterly Report on Form 10-Q for the Period Ended November 27, 2022

Lifecore Biomedical, Inc. announced that it has received $38.75 million in funding from Legion Partners Asset Management, LLC, 22NW, LP, 325 Capital, LLC, Cove Street Partners, Wynnefield Capital, Inc.

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. announced that it has received $5.003136 million in funding

Price target decreased to US$13.75

Landec Corporation Reiterates Revenue Guidance for the Full Year Fiscal 2023

Landec Non-GAAP EPS of -$0.32, revenue of $43.35M

Landec Corporation to Report Q1, 2023 Results on Oct 06, 2022

Landec Corporation, Annual General Meeting, Nov 01, 2022

Landec Corp. Receives Notice from Nasdaq Regarding Delayed Annual Report

Landec receives Nasdaq's notification on delayed annual report filing

Landec Corporation announced delayed annual 10-K filing

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Provides Revenue Guidance for the Full Year Fiscal 2023

VP & President of Lifecore exercised options to buy US$76k worth of stock.

Laughing Water Capital - Landec Corp. : A High Quality CDMO

Landec Corporation(NasdaqGS:LNDC) dropped from Russell 2000 Value-Defensive Index

Landec (NASDAQ:LNDC) Takes On Some Risk With Its Use Of Debt

Independent Director exercised options to buy US$70k worth of stock.

CEO, President & Director exercised options to buy US$269k worth of stock.

High number of new directors

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Reiterates Consolidated Earnings Guidance for the Fiscal Year 2022

Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet

High number of new directors

Independent Director recently bought US$104k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Provides Consolidated Revenue Guidance for Full Year Fiscal 2022

Price target increased to US$15.00

Consensus revenue estimates fall by 66%

Here's What's Concerning About Landec's (NASDAQ:LNDC) Returns On Capital

Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products

Landec Corporation Provides Earnings Guidance for the First Half, Second Half and Full Year of Fiscal 2022

First quarter 2022 earnings released: US$322 loss per share (vs US$0.38 loss in 1Q 2021)

Landec Still In Play As An Activist Investment

Independent Director Patrick Walsh has left the company

Consensus forecasts updated

Price target increased to US$14.40

Full year 2021 earnings released: US$1.12 loss per share (vs US$1.31 loss in FY 2020)